External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations DOI Creative Commons

Britton Scheuermann,

Alexandra R. Brown, Trenton D. Colburn

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(10), P. e2438311 - e2438311

Published: Oct. 11, 2024

Importance The American Heart Association’s Predicting Risk of Cardiovascular Disease Events (PREVENT) equations were developed to extend and improve on previous cardiovascular disease (CVD) risk assessments for the purpose treatment initiation patient-clinician communication. Objective To assess prognostic capabilities, calibration, discrimination PREVENT in a study sample representative noninstitutionalized, US general population. Design, Setting, Participants This used data from National Health Nutrition Examination Survey (NHANES) 1999 2010 cycles. included adults whom 10-year follow-up available. Data curation analyses took place December 2023 through May 2024. Main Outcomes Measures Primary measures estimated by equations, as well estimates Pooled Cohort Equations (PCEs). primary outcome was composite CVD-related mortality at 10 years follow-up. Additional compared against PCEs. Model assessed with receiver-operator characteristic curves Harrell C statistic proportional hazard regression; model calibration determined slope predicted versus observed risk. Results cohort, accounting NHANES complex survey design, consisted 172.9 million participants (mean age, 45.0 [95% CI, 44.6-45.4 years]; 52.1% women 51.5%-52.6%]). In adjusted 1% increase statistically significantly associated increased CVD (hazard ratio, 1.090; 95% 1.087-1.094). scores demonstrated excellent (C statistic, 0.890; 0.881-0.898) but moderate underfitting (calibration slope, 1.13; 1.06-1.21). models performed better than PCEs, net reclassification index (0.093; 0.073-0.115). Conclusions Relevance this only modest discrepancies calibration. These findings provided evidence supporting utilization application intended population suggested Association.

Language: Английский

Cardiovascular disease and cancer: shared risk factors and mechanisms DOI
Nicholas S. Wilcox,

Uri Amit,

Jacob B. Reibel

et al.

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(9), P. 617 - 631

Published: April 10, 2024

Language: Английский

Citations

80
Cardiovascular Considerations After Cancer Therapy DOI Creative Commons
Anne Blaes, Anju Nohria, Saro H. Armenian

et al.

JACC CardioOncology, Journal Year: 2025, Volume and Issue: 7(1), P. 1 - 19

Published: Jan. 1, 2025

Language: Английский

Citations

2
Higher Prevalence of Long COVID Observed in Cancer Survivors: Insights from a US Nationwide Survey DOI

Lingchen Wang,

Wei Yang

Annals of Epidemiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

2
Atherosclerosis With Immune Checkpoint Inhibitor Therapy DOI
Giselle Alexandra Suero-Abreu, Markella V. Zanni, Tomas G. Neilan

et al.

JACC CardioOncology, Journal Year: 2022, Volume and Issue: 4(5), P. 598 - 615

Published: Dec. 1, 2022

Language: Английский

Citations

61
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis DOI Creative Commons
Akhmetzhan Galimzhanov, Sedralmontaha Istanbuly, Han Naung Tun

et al.

European Journal of Preventive Cardiology, Journal Year: 2023, Volume and Issue: 30(18), P. 2018 - 2031

Published: July 26, 2023

It is unclear whether the future risk of cardiovascular events in breast cancer (Bc) survivors greater than general population. This meta-analysis quantifies disease development Bc patients, compared to a matched cancer-free population, and reports incidence patients with Bc.

Language: Английский

Citations

25
AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring DOI Creative Commons

Luiza Nechita,

Dana Tutunaru,

Aurel Nechita

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(6), P. 787 - 787

Published: March 20, 2025

The increasing prevalence of cardiovascular complications in cancer patients due to cardiotoxic treatments has necessitated advanced monitoring and predictive solutions. Cardio-oncology is an evolving interdisciplinary field that addresses these challenges by integrating artificial intelligence (AI) smart cardiac devices. This comprehensive review explores the integration devices cardio-oncology, highlighting their role improving risk assessment early detection real-time cardiotoxicity. AI-driven techniques, including machine learning (ML) deep (DL), enhance stratification, optimize treatment decisions, support personalized care for oncology at risk. Wearable ECG patches, biosensors, AI-integrated implantable enable continuous surveillance analytics. While advancements offer significant potential, such as data standardization, regulatory approvals, equitable access must be addressed. Further research, clinical validation, multidisciplinary collaboration are essential fully integrate solutions into cardio-oncology practices improve patient outcomes.

Language: Английский

Citations

1
Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer DOI Creative Commons
Aderonke Abiodun, Chengsheng Ju, Catherine Welch

et al.

JACC CardioOncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Fluoropyrimidine chemotherapy is administered first-line for many gastrointestinal cancers. However, patients with cardiovascular disease commonly receive alternative treatment due to cardiotoxicity concerns. The study sought assess the risks of all-cause mortality and acute events fluoropyrimidine treatment. We conducted an observational cohort applying a target trial emulation framework linked national cancer, cardiac, hospitalization registry data from Virtual Cardio-Oncology Research Initiative. Adults diagnosed tumors eligible fluoropyrimidine-based as therapy were included. All-cause composite (acute coronary syndrome, heart failure, cardiac arrhythmia, intervention, arrest, death) compared in treated vs management. Adjusted, weighted pooled logistic regression models used estimate 1-year risk difference (RD). Among 103,110 (mean age 69.7 years, 59% male), absolute death at 1 year was significantly lower fluoropyrimidine-treated (RD: -7.7%; 95% CI: -8.7% -6.7%) small increased 0.9%; 0.0% 1.9%). This primarily arrhythmias 0.8%; 0.1% 1.6%) arrest 0.3%; 0.5%), no syndromes including subgroup pre-existing artery disease. markedly improved overall survival fluoropyrimidines cancer outweighs arrhythmia arrest. Oncologists should take this into consideration decision making avoid undue clinical conservatism, particularly

Language: Английский

Citations

1
The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention DOI Creative Commons

Arielle Abovich,

Daniel S. Matasic, Rhanderson Cardoso

et al.

American Journal of Preventive Cardiology, Journal Year: 2023, Volume and Issue: 15, P. 100527 - 100527

Published: July 30, 2023

The prevalence of heart failure (HF) in the United States (U.S.) is estimated at over 6 million adults, with incidence continuing to increase. A large proportion U.S. population also risk HF due high established factors, such as hypertension, diabetes, and obesity. Many individuals have multiple placing them even higher risk. In addition, these factors disproportionately impact various racial ethnic groups. Recognizing rising health economic burden U.S., 2022 American Heart Association / College Cardiology Failure Society America (AHA/ACC/HFSA) Guideline placed a strong emphasis on prevention HF. purpose this review highlight role both primary secondary HF, outlined by recent guideline, address preventive cardiology community reducing at-risk individuals.

Language: Английский

Citations

19
Associations Between Social Determinants of Health and Cardiovascular Health of U.S. Adult Cancer Survivors DOI Creative Commons
Danish Iltaf Satti, Jeffrey Shi Kai Chan, Edward Christopher Dee

et al.

JACC CardioOncology, Journal Year: 2023, Volume and Issue: 6(3), P. 439 - 450

Published: Oct. 24, 2023

Relationships between the social determinants of health (SDOH) and cardiovascular (CVH) cancer survivors are underexplored. The study sought to investigate associations SDOH CVH adult survivors. Data from U.S. National Health Interview Survey (2013-2017) were used. Participants reporting a history included, excluding those with only nonmelanotic skin cancer, or missing data for any domain CVH. was quantified 6-domain, 38-item score, consistent Centers Disease Control Prevention recommendations (higher score indicated worse deprivation). based on American Heart Association's Life's Essential 8, but due unavailable detailed dietary data, 7-item used, higher indicating Survey-specific multivariable Poisson regression used test quartiles Altogether, 8,254 subjects analyzed, representing population 10,887,989 persons. Worse associated (highest vs lowest quartile: risk ratio 1.30; 95% CI: 1.25-1.35; P < 0.001), grossly linear relationship scores. Subgroup analysis found significantly stronger in younger participants (Pinteraction = 0.026) women 0.001) without significant interactions race 0.051). Higher scores all domains independently (all 0.001). also each component 0.05 highest quartile). An unfavorable profile among United States.

Language: Английский

Citations

19
Cardiovascular health assessment in routine cancer follow-up in community settings: survivor risk awareness and perspectives DOI Creative Commons
Kathryn E. Weaver, Emily V. Dressler, Sydney Smith

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Jan. 31, 2024

Abstract Background Guidelines recommend cardiovascular risk assessment and counseling for cancer survivors. For effective implementation, it is critical to understand survivor health (CVH) profiles perspectives in community settings. We aimed (1) Assess CVH profiles, (2) compare self-reported EHR-based categorization of factors, (3) describe perceptions regarding addressing during oncology encounters. Methods This cross-sectional analysis utilized data from an ongoing NCI Community Oncology Research Program trial EHR heart tool survivors (WF-1804CD). Survivors presenting routine care after potentially curative treatment recruited 8 practices completed a pre-visit survey, including American Heart Association Simple 7 factors (classified as ideal, intermediate, or poor). Medical record abstraction ascertained CVD characteristics. Likert-type questions assessed desired discussion care. Results Of 502 enrolled (95.6% female; mean time since diagnosis = 4.2 years), most had breast (79.7%). Many common comorbidities, high cholesterol (48.3%), hypertension BP (47.8%) obesity (33.1%), diabetes (20.5%); 30.5% received cardiotoxicity potential treatment. Less than half ideal/non-missing levels physical activity (48.0%), BMI (18.9%), (17.9%), blood pressure (14.1%), healthy diet (11.0%), glucose/ HbA1c (6.0%). While > 50% concordant EHR-self-report smoking, BMI, pressure; cholesterol, glucose, A1C were unknown by and/or missing the most. Most agreed providers should talk about (78.9%). Conclusions Tools promote can fill gaps knowledge are likely be well-received Trial registration NCT03935282, Registered 10/01/2020

Language: Английский

Citations

7